Inotersen - Akcea Therapeutics/Ionis Pharmaceuticals

Drug Profile

Inotersen - Akcea Therapeutics/Ionis Pharmaceuticals

Alternative Names: GSK 2998728; Human transthyretin antisense oligonucleotide - Akcea Therapeutics/Ionis Pharmaceuticals; Inotersen; Inotersen sodium - Akcea Therapeutics/Ionis Pharmaceuticals; IONIS-TTRRx; ISIS 420915 salt; ISIS-420915; ISIS-GSK1Rx; ISIS-TTRRx; Phosphorothioate oligonucleotide - Akcea Therapeutics/Ionis Pharmaceuticals; TEGSEDI

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Akcea Therapeutics; GlaxoSmithKline; Indiana University School of Medicine; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides; Neuroprotectants
  • Mechanism of Action Prealbumin expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Amyloid polyneuropathy
  • Phase II Amyloidosis; Cardiomyopathies

Most Recent Events

  • 07 Aug 2018 PTC Therapeutics announces intention to submit regulatory application in Latin America
  • 06 Aug 2018 Akcea Therapeutics intends to launch inotersen in Germany after Summer 2018
  • 02 Aug 2018 Inotersen licensed to PTC Therapeutics in Latin America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top